Given that ZNF217 amplifications have been detected in 8-29% of breast cancers [1] and that high ZNF217 expression levels are not necessarily correlated to increased ZNF217 gene copy numbers in breast cancer cells [4,5,10], increased protein expression of ZNF217 could represent a new mechanism by which breast cancer cells without ZNF217 gene amplification become resistant to paclitaxel. Here, ZNF217 is linked to breast cancer.